A lifetime of losing weight: Trying and failing to slim down is far more common than you may think
The recent double-blinded poll, of 2,000 U.S. women between the ages of 30 and 65, conducted by Talker Research on behalf of Boston Scientific, found that 78% have tried to lose weight before, but many struggle to reach their weight loss goals.
Women who have tried to lose weight in the past shared numerous methods they've tried to reach their goals, including a healthier diet (78%), weight loss supplements (41%), weight loss beverages (39%), and fad diets (31%).
Results found some have also tried turning to modern medicine or procedures for weight loss: 14% reported trying GLP-1 medications, and 7% tried either bariatric surgeries or endoscopic procedures.
5 A new study has found that the average woman tries to lose weight seven times over their lifespan – but fails six times.
Tetiana – stock.adobe.com
Three in four women (74%) said weight loss is important to their personal overall health and wellbeing.
And for most who have tried to lose weight before, the biggest motivators were to maintain their appearance (65%), their physical health (63%), and their personal satisfaction (59%).
Many said they're influenced to try new weight loss methods by doing their own personal research (42%) or seeking advice from healthcare professionals (34%).
Four in 10 (41%) admitted they're unhappy with their current weight, and 43% said their weight has decreased their sense of self-confidence.
5 Many said they're influenced to try new weight loss methods by doing their own personal research or seeking advice from healthcare professionals.
SWNS
A third would consider a weight loss procedure or surgery. However, 48% have hesitations about it, stating they wouldn't consider undergoing weight loss surgery to assist in reaching their goals.
People are just learning about the endobariatric options. Nearly half (47%) of those who have tried to lose weight before said they were not aware of minimally invasive, endoscopic procedures for weight loss, and only 2% of them had undergone an endobariatric procedure.
But 51% said they'd be interested in learning more about it and what it can do for them. In fact, 74% who are unhappy with their weight believe it's important that they have multiple options to choose from for weight loss.
5 Seven in 10 women who are unhappy with their current weight believe the ease of implementation and access are important when deciding on a new weight loss method.
SWNS
Reem Sharaiha, MD, MSc*, attending physician and director of endoscopy at New York Presbyterian Hospital/Weill Cornell Medical Center, said: 'Losing weight is an extremely relatable goal among women and something most have tried to do at some point in their lives.
'It can be a challenging and overwhelming process that often involves many factors and motivators to be successful.
'It is important to understand that obesity is not anyone's fault and can be multifactorial. We need to treat obesity as a chronic condition requiring multiple different treatment options during different stages of a person's life.'
5 The recent double-blinded poll found that 78% have tried to lose weight before, but many struggle to reach their weight loss goals.
SWNS
Seven in 10 women who are unhappy with their current weight believe the ease of implementation and access are important when deciding on a new weight loss method.
Respondents unhappy with their current weight shared what they believe would help them achieve their weight loss goals more effectively: self-motivation (61%), improved finances and ability to afford weight loss treatments under insurance (37%), an increased focus on their health goals (33%), access to weight loss programs (30%) and access to weight loss procedures (27%).
Sharaiha added: 'Endobariatric procedures may be an excellent option for women looking to lose weight and maintain their weight loss through a healthy diet and exercise.
5 Results found some have also tried turning to modern medicine or procedures for weight loss: 14% reported trying GLP-1 medications, and 7% tried either bariatric surgeries or endoscopic procedures.
SWNS
'For those who want to avoid weight loss medications and surgery, an endobariatric procedure can be an effective alternative to kickstart healthy weight loss. I encourage women to talk to their doctor to determine if this may be a good option for their weight loss journey.'
*Dr. Reem Sharaiha is a paid consultant of Boston Scientific Corporation. She has not been compensated in connection with this research or news copy.
Survey methodology:
Talker Research surveyed 2,000 American women, aged 30 to 65; the survey was commissioned by Boston Scientific and administered and conducted online by Talker Research between Nov. 1 and Nov. 7, 2024.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
4 hours ago
- Forbes
A New Chapter For Diabetes—and Regenerative Medicine
For decades, the ambitious goal of regenerative medicine has been to replace damaged or lost tissues with healthy, functioning ones. Nowhere is this objective more compelling—or challenging—than in type 1 diabetes. Countless research efforts over the years have sought to restore these cells. Breakthroughs in cell engineering and transplantation are beginning to overcome long-standing roadblocks, and these recent advances are a significant achievement for regenerative medicine as a whole. For millions living with the constant demands and worries of type 1 diabetes, this is more than promising data. It's a moment that hints at a world where glucose monitors and needles might finally become relics of the past. With this, a life free from the daily burdens of diabetes suddenly feels not just possible, but Is Type 1 Diabetes? Type 1 diabetes is a chronic autoimmune disorder defined by the immune system's destruction of insulin-producing beta cells in the pancreas. Insulin is the hormone responsible for moving glucose from the bloodstream into the body's cells for energy. Without it, blood sugar rises to dangerous levels. Over time, it can damage virtually every organ. Most people diagnosed are children or young adults, and living with type 1 diabetes requires ongoing vigilance: regular blood glucose testing, carefully calibrated insulin administration, and persistent risk of life-threatening hypoglycemia. To survive, people with type 1 diabetes must monitor their blood sugar levels constantly. They frequently perform fingerstick tests throughout the day to check their blood glucose levels. Also, they must adjust their diet, exercise routine, and daily schedule to accommodate frequent insulin injections or an insulin pump. Despite advances in technology, keeping blood glucose within a safe range remains challenging, and the risk of life-threatening 'hypoglycemic' episodes—when blood sugar drops too low—is Stem Cell Therapy: Replacing What's Lost This is where the new therapies come into play. They go straight to the heart of the problem: the loss of the body's own insulin-producing cells. Instead of requiring patients to rely on lifelong injections, the focus is now on developing stem cells grown in controlled laboratory environments. These stem cells are engineered to become fully functional islet cells. These are the very clusters that regulate blood sugar in a healthy pancreas. The "off-the-shelf" nature of these cells is crucial. Earlier islet transplant procedures relied on donated organs, which are rare, variable in quality, and subject to lengthy waitlists. The engineered cells, on the other hand, are produced in large quantities. Also, they can be made available as needed. When infused, typically into the liver, these new cells integrate and begin responding to blood sugar levels in real time, releasing insulin as needed. In essence, the therapy is designed to restore the natural balance lost due to the disease. The promise of this approach is already becoming a the Latest Study The most recent results in the development of stem cell–derived therapies for type 1 diabetes stem from a clinical trial conducted by Vertex Pharmaceuticals. This study enrolled patients with established, severe type 1 diabetes. This is a group for whom current treatments often fail to prevent sudden and dangerous drops in blood sugar. Each patient in the trial received a single infusion of lab-grown islet cells, now referred to as zimislecel. To translate the science: the stem cells are first turned into insulin-producing islet cells in the lab. These are then infused into the patient's liver, not the pancreas. If successful, they begin sensing blood sugar levels and releasing insulin as needed, just like a healthy pancreas would. Think of this as swapping out a faulty part with a working one, rather than relying on external fixes. The results over twelve months were consistent and dramatic. All participants in the study were found to be producing their own insulin again. This was confirmed by checking bloodwork to verify that the islet cells were now active. Therefore, the transplanted cells integrated well, and the patients' bodies were able to produce insulin naturally for the first time in years. Even more remarkably, ten of these individuals were able to discontinue daily insulin injections entirely. Every participant met or surpassed the American Diabetes Association's stringent targets for glycemic control. Notably, none suffered severe hypoglycemic This Matters: The Science and Its Impact These results represent a shift in the care landscape for type 1 diabetes. Previous attempts at islet cell replacement used donor cells, which were in very limited supply. By creating islets from universal stem cells, this therapy can be scaled up. It brings the possibility of universal therapies with consistent quality and availability. This offers real hope to millions worldwide. It also signals a foundational advance in regenerative medicine itself. Demonstrating that we can produce, transplant, and integrate functional cell populations to cure a chronic, complex condition illustrates the practical power of stem cell technology. The methodology used here is already being adapted for other therapeutic targets: engineered heart muscle for cardiac repair, retinal cells for vision restoration, and dopaminergic neurons for Parkinson's disease. It establishes a blueprint for tackling similar disorders and builds a bridge from bench research to real-world clinical impact. These advances, however, are not without their complexities. Because the transplanted islet cells are not the patient's own, recipients currently require immunosuppressive medications to prevent rejection—a challenge shared by all current forms of tissue and organ transplantation. Although initial safety profiles are encouraging and side effects manageable, ongoing studies are exploring methods to reduce or eliminate immune suppression, such as gene editing and immune cloaking Road Ahead: What's Next? The achievements described here are far more than incremental progress in diabetes care. They represent proof-of-concept for the broad ambitions of regenerative medicine: restoring lost tissue function, curing chronic diseases, and making transformative treatments widely accessible. As these strategies mature and diversify, their impact will almost certainly extend well beyond any single disease. They offer a pathway to fundamentally change how we approach a broad spectrum of degenerative and autoimmune conditions. The future of regenerative medicine, once hypothetical and distant, now approaches with real hope for curing—not simply managing—a host of devastating chronic conditions.
New York Post
4 hours ago
- New York Post
Skimping out on your lunch break? Here's how many employed Americans actually stop to eat
More than half of Americans skip lunch in order to work more, according to a recent survey. The poll of 2,000 employed Americans, with a quota of 1,000 working parents with school-aged kids, revealed that 55% forgo eating lunch on hectic days to be more productive. Advertisement Respondents also admitted to completely forgetting to eat lunch two days out of the work week, on average. In fact, more than four in 10 workers (43%) rely on reminders to eat a midday meal, with women being significantly more likely than men (63% vs. 48%) to need a reminder to eat during the workday. Commissioned by Buddig for National Sandwich Month in August and conducted by Talker Research, the survey found that although 63% of working Americans eat a full, substantial meal for lunch most days, a significant number (37%) confessed to eating more of a snack for lunch, or grazing on little snack foods throughout the day in place of a meal. 7 More than four in 10 workers (43%) rely on reminders to eat a midday meal, according to reports. Martin Barraud/Caia Image – Advertisement More than one in 10 (13%) also admitted they'll typically work and eat lunch at the same time on a regular workday, instead of taking a break from their tasks to eat. Looking at differences between subgroups, men (91%) are more likely than women (85%) to pause their work to eat lunch, and hybrid workers (94%) are more likely than remote (85%) and in-person employees (87%) to take a true lunch break. A third of employed Americans (33%) also revealed that they'll usually eat their midday meal at their desk or workstation, with remote workers being more guilty of this (41%) than hybrid (38%) and in-person (28%) respondents. On average, workers eat lunch at 12:48 p.m., and their typical lunch hour is actually only 35 minutes, on average. Advertisement 7 More than half of Americans skip lunch in order to work more, according to a recent survey. SWNS / Buddig for National Sandwich Month 7 37% of respondents confessed to eating more of a snack for lunch, or grazing on little snack foods throughout the day in place of a meal. SWNS / Buddig for National Sandwich Month For those who step away from their work to eat, many (43%) multitask during their downtime, with women being more likely than men (51% vs. 33%) to multitask while eating lunch. And multitaskers most commonly check social media (70%), text (64%), and make phone calls (55%) during their lunch hours, even though most respondents (84%) agreed that taking offline lunch breaks, sans screens or technology, is good for their health. Advertisement 'While it can be tempting to power through your workday and skip taking a lunch, it's important to give yourself a break and eat a full, substantial meal,' said Amy Krider, senior brand manager at Buddig. 'Not only do we need all the energy we can get from a filling meal to do our best work, we also need little breaks from our screens and tasks during the day as well for our health and wellness.' On a typical workday, 62% of employed Americans usually bring lunch from home, a third (33%) will buy it, and 5% are lucky enough to have their meal provided by their employer. 7 A third of employed Americans (33%) also revealed that they'll usually eat their midday meal at their desk or workstation. goodluz – Three-quarters of workers (75%) said that sandwiches are their go-to lunch meal, and 70% of those with school-aged kids said their kids also include sandwiches among their lunchtime favorites. Looking closer at mealtime menus for both parents and kids, working Americans cited sandwiches (64%), salads (45%) and hamburgers (33%) as their most common lunch staples, and those with kids in school said their children will eat sandwiches (58%), pre-made meal kits (36%) and pizza (30%) most often. Health-wise, the quality of working parents' meals falls a bit behind their kids'. While 83% of parents with school-aged kids said their children's lunches are healthy, only 74% could say the same for themselves. 7 Three-quarters of workers said that sandwiches are their go-to lunch meal, according to the survey. SWNS / Buddig for National Sandwich Month 7 While 83% of parents with school-aged kids said their children's lunches are healthy, only 74% could say the same for themselves. SWNS / Buddig for National Sandwich Month Advertisement The results also revealed that hybrid workers reported eating the healthiest lunches (79%) compared to remote (71%) and in-person (65%) workers. And surprisingly, those whose lunches are catered by their employers reported having healthier lunches (75%) than those who bring homemade lunches (72%) and buy lunch (62%). 7 rh2010 – 'Busy work schedules mean that many don't have time to pack healthy, protein-filled lunches,' said Krider. 'And working parents have the added struggle of making sure their kiddos get nutritious, filling meals while at school. That's where the classic sandwich can come in handy. Protein-filled and versatile, it's included among respondents' favorite lunch meals for a reason.' Advertisement Survey methodology: Talker Research surveyed 2,000 employed Americans with a quota of 1,000 parents of school-aged children; the survey was commissioned by Buddig and administered and conducted online by Talker Research between July 15 and July 18, 2025.
Business Wire
6 hours ago
- Business Wire
Marea Therapeutics Enrolls First Participant in Phase 1 Clinical Study Evaluating MAR002 for Acromegaly
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that the first participant has been enrolled in Marea's Phase 1 study evaluating MAR002 for the treatment of acromegaly. Acromegaly is a chronic, rare, systemic disease most often caused by a growth hormone (GH)-secreting pituitary adenoma, leading to the overproduction of insulin-like growth factor 1 (IGF-1) which mediates the characteristic somatic overgrowth and multisystem involvement observed in affected individuals. The primary objective of medical therapy for acromegaly is to normalize IGF-1 levels according to age and sex. 'Dosing our first participant in this Phase 1 study of MAR002 is a critical milestone for Marea Therapeutics and brings us closer to addressing the significant unmet needs of patients with acromegaly,' said Josh Lehrer, M.D., chief executive officer of Marea Therapeutics. 'We believe MAR002's unique properties, including an allosteric mechanism of action, could make it a differentiated and optimal medical therapy for acromegaly, increasing the effectiveness and reducing the burden associated with current therapies.' The MAR-201 study is a first-in-human (FIH), randomized, blinded, parallel-group, placebo-controlled single ascending dose (SAD) study in healthy men. Key objectives of the study include: Primary Objective: To evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002, assessed by treatment-emergent adverse events (TEAEs), vital signs, physical examinations, safety laboratories, and electrocardiograms (ECGs). Secondary Objective: To evaluate the pharmacokinetics (PK) of SC administration of MAR002 Exploratory Objectives: To evaluate the effect of SC administration of MAR002 on serum IGF-1 levels (pharmacodynamics [PD]/efficacy) and to assess the immunogenicity. About MAR002 MAR002 is a potent and selective half-life-extended, allosteric, human monoclonal growth hormone receptor antagonist (GHRA) antibody being developed for the treatment of acromegaly. The in vivo PK and PD properties of MAR002 are predictable and typical of a half-life extended human antibody, showing a long duration of action compatible with infrequent subcutaneous dose administration in humans. These characteristics support its potential to offer an effective and convenient treatment for patients with acromegaly. About Acromegaly Acromegaly is an orphan disease characterized by the excess secretion of growth hormone (GH) from a benign pituitary adenoma. Acromegaly affects approximately 30,000 patients in the U.S. If left untreated, acromegaly is highly morbid, leading to significant comorbidities such as GH-induced insulin resistance and diabetes, and serious cardiovascular pathology. The median lifespan of patients can be shortened by 10 years without effective therapy, and incomplete IGF-1 normalization is associated with increased mortality. Despite its severity, acromegaly is often under or misdiagnosed, with an average time from symptom onset to diagnosis of approximately eight years. The current treatment paradigm for acromegaly often involves surgery, performed in over 90% of patients, which achieves remission in about 50% of cases, though this can degrade over time. Medical therapy is required for approximately 65% (around 20,000 in the U.S.) of patients during their disease journey. Current medical treatments include somatostatin receptor ligands (SRLs) and growth hormone receptor antagonist (GHRA) pegvisomant. However, most patients do not achieve biochemical control with existing therapies. About Marea Therapeutics Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company's lead therapy, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for atherosclerotic cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit and follow us on LinkedIn and X.
